F. Hoffmann-La Roche Ltd: FDA approves Roche's Polivy in com

Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma

Related Keywords

Switzerland , United States , Lugano , Ticino , Japan , America , Mabthera Rituxan , Bruno Eschli , Sabine Borngr , Nathalie Altermatt , Birgit Masjost , Loren Kalm , Levi Garraway , Gerard Tobin , Roche Group Media Relations , Lymphoma Academic Research Organisation , Roche Group , Head Of Global Product Development , Lymphoma Study Association , International Prognostic Index , Genentech , Drug Administration , Chief Medical Officer , Global Product , Lugano Response Criteria , Lymphoma Academic Research , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Hoffmann , Oche , Pproves , Polivy , Combination , People , Certain , Types , Reviously , Untreated , Diffuse , Barge , Fell , Lymphoma ,